-+ 0.00%
-+ 0.00%
-+ 0.00%

MetLife's Premium Growth May Not Cover What's Quietly Shrinking

Barchart·11/03/2026 16:18:12
Listen to the news
Barchart +0.43% Beat Dec 2025 $2.36 $2.58 +9.32% Beat Mar 2026 $2.25 $2.42 +7.56% Beat Jun 2026 $2.30 $2.43 +5.65% Beat

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

MetLife reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full reaction to the actual numbers.

Earnings Date Day 0 Move Day 0 Range Day +1 Move Day +1 Range
2026-08-05 +$0.13 (+0.14%) $1.77 (1.84%) +$3.69 (+3.83%) $2.80 (2.91%)
2026-05-06 +$0.26 (+0.33%) $1.55 (1.94%) -$1.34 (-1.67%) $3.17 (3.96%)
2026-02-04 +$1.11 (+1.44%) $1.88 (2.44%) -$2.69 (-3.45%) $6.78 (8.70%)
2025-11-05 -$0.78 (-0.98%) $1.58 (1.98%) -$2.71 (-3.44%) $6.10 (7.75%)
2025-08-06 +$1.06 (+1.42%) $1.36 (1.82%) -$2.13 (-2.80%) $2.84 (3.74%)
2025-04-30 -$1.05 (-1.37%) $2.28 (2.98%) +$0.40 (+0.53%) $2.48 (3.30%)
2025-02-05 +$0.37 (+0.44%) $1.22 (1.44%) -$1.33 (-1.56%) $3.27 (3.84%)
2024-10-30 +$0.35 (+0.42%) $1.14 (1.38%) -$4.76 (-5.72%) $3.09 (3.71%)
Avg Abs Move 0.82% 1.98% 2.88% 4.74%

MetLife's post-earnings price behavior shows moderate Day 0 volatility averaging 0.82%, but significantly larger Day +1 moves averaging 2.88% as the market digests results. The Day +1 range averages 4.74%, indicating substantial intraday volatility in the session following the release. Recent history shows mixed directional outcomes: the most recent report (August 2026) saw a muted Day 0 move of +0.14% followed by a strong Day +1 gain of +3.83%, while the prior quarter (May 2026) posted a small Day 0 gain of +0.33% but reversed to a -1.67% Day +1 decline. The two November reports in this series (2025 and prior) both produced negative Day +1 moves exceeding -3.4%, suggesting seasonal or cyclical factors may influence Q3 reactions. Overall, investors should expect the bulk of price action to occur in the Day +1 session, with historical moves ranging from -5.72% to +3.83% and an average absolute magnitude near 3%.

Part 2.2: Options Market Expected Move

Metric Value
Expiration Date 11/20/26 (DTE 17)
Expected Move $5.19 (5.15%)
Expected Range $95.49 to $105.86
Implied Volatility 37.11%

The options market is pricing a 5.15% move for the November 20 expiration, which is notably larger than the 2.88% average Day +1 move observed in recent earnings history. This 5.15% expected move also exceeds the 4.74% average Day +1 range, suggesting options traders are positioning for above-average volatility — possibly reflecting heightened uncertainty around the elevated earnings bar or anticipation of significant guidance commentary.

Part 3: What Analysts Are Saying

Analysts maintain a Moderate Buy consensus on MetLife with an average rating of 4.32 out of 5.0, reflecting strong bullish conviction. The breakdown shows 12 Strong Buys, 1 Moderate Buy, and 6 Holds, with zero sell ratings. This distribution underscores broad confidence in the company's earnings trajectory and business fundamentals.

The average price target stands at $109.23, implying +8.5% upside from the current $100.67 price. The range of targets is wide, spanning from a low of $87.00 to a high of $119.00, with the upper end suggesting some analysts see potential for double-digit gains if execution remains strong and valuation multiples expand.

Sentiment has remained unchanged over the past month, with the rating count and average recommendation holding steady at 4.32. This stability suggests analysts are maintaining their bullish stance heading into the Q3 release rather than adjusting views preemptively. The lack of recent downgrades or upgrades indicates the Street is waiting for the earnings print and management commentary before making fresh calls, though the existing consensus reflects confidence that MetLife can meet or exceed the $2.71 estimate and sustain its growth trajectory into 2027.

Part 4: Technical Picture

MetLife enters earnings with strong technical momentum across all timeframes. The Barchart Technical Opinion currently stands at 100% Buy, up from 100% Buy last week and 80% Buy a month ago, indicating strengthening conviction in the uptrend.

Timeframe Analysis:

  • Short-term (100% Buy): Strong buy signal indicates robust near-term momentum heading into the earnings release
  • Medium-term (100% Buy): Bullish reading confirms the intermediate-term trend remains firmly positive
  • Long-term (100% Buy): Strong buy signal reflects sustained strength in the longer-term trend structure

Trend Characteristics: The signal strength is classified as Strong with a Strengthening direction, suggesting the technical environment is increasingly supportive as earnings approach.

The stock is trading at $100.67, positioned above all key moving averages: the 5-day ($100.42), 10-day ($100.67), 20-day ($100.08), 50-day ($97.90), 100-day ($95.24), and 200-day ($85.92). This alignment confirms a well-established uptrend with rising support levels. The stock has gained ground steadily over recent months, now trading +17.2% above its 200-day average, reflecting sustained buying interest.

Period Value Period Value
5-Day MA $100.42 50-Day MA $97.90
10-Day MA $100.67 100-Day MA $95.24
20-Day MA $100.08 200-Day MA $85.92

Key resistance may emerge near the $105.86 level implied by the options expected move, while support appears solid at the 50-day average around $97.90. The technical setup is highly supportive heading into earnings, with momentum indicators, moving average alignment, and the strengthening Barchart Opinion all pointing to bullish positioning. However, the stock's proximity to recent highs and the elevated options-implied move suggest the market is pricing meaningful risk around the release — a strong beat could propel shares toward the $109–$119 analyst target range, while any disappointment could trigger profit-taking given the extended technical position.

This article was generated using Barchart’s automated content technology and existing data APIs. As a result, we are able to provide readers with timely, actionable, in-depth analysis on more equities, allowing them to make more informed decisions. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy here. And, if you would like to report any inaccuracies, please contact news@barchart.com.